Genomics Expenditures and National Security Enhancement Act of 2023
A BILL
To strengthen the requirements for reviews by the Committee on Foreign Investment in the United States of covered transactions involving genetic information, and for other purposes.
Sec. 2 Requirements for reviews of covered transactions involving genetic information
“(cc) Covered transactions involving genetic information—The parties to a covered transaction shall submit a declaration described in subclause (I) with respect to the transaction if the transaction involves an investment described in subsection (a)(4)(B)(iii)(III) by a foreign person in a United States business that maintains or collects information about genetic tests of United States citizens, including any such information relating to genomic sequencing.”
“(A) In general—The chairperson”
“(B) Covered transactions involving genetic information—The chairperson shall consult with the Secretary of Health and Human Services in any review or investigation under subsection (a) of a covered transaction that involves an investment described in subsection (a)(4)(B)(iii)(III) by a foreign person in a United States business that maintains or collects information about genetic tests of United States citizens, including any such information relating to genomic sequencing.”
Sec. 3 Expansion of committees receiving annual testimony from Committee on Foreign Investment in the United States
“(2) Committees specified—The committees specified in this paragraph are—
“(A) the Committee on Banking, Housing, and Urban Affairs, the Committee on Foreign Relations, and the Select Committee on Intelligence of the Senate; and
“(B) the Committee on Financial Services, the Committee on Foreign Affairs, and the Permanent Select Committee on Intelligence of the House of Representatives.”